Regulation of the sale of medicine in Denmark – with Ozempic as a case

The sale of prescription medicine sold at pharmacies is subject to extensive regulation in Denmark. The regulation aims to support certain health policy considerations such as equal and easy access to safe and effective medicine. The public sector’s expenditure on reimbursement related to patients’ use of Ozempic amounted to approximately DKK 1.3 billion in 2023, corresponding to 16 percent of the public sector’s total expenditure on medicines sold at pharmacies.

The Danish Competition Council has previously analysed the sale of medicine sold at Danish pharmacies. In this article, the Competition Council follows up on its previous analyses and takes a closer look on the sale of Ozempic in Denmark.

Read the article (in Danish)